BIT (ASX) BIT Charting

Originally posted by jebby: ↑

Aquestion to AI Copilot
How long does it usually take to analyse thousands of data sets in a phase 2 trial by a biotech company using athird party to analyse the results?

The Answer
Analyzing thousandsof data sets in a Phase2 clinical trial is a complex process that involves several factors. While the exact duration can vary based on the specifics of the trial, here are some key considerations:
Data Collection: Before analysis begins, data must be collected from the trial participants. This includes information related to the treatment, patient demographics, adverse events, and other relevant variables. The time required for data collection depends on the trial’s duration and the number of participants.
Data Cleaning and Preparation: Raw data often contains errors, missing values, and inconsistencies. Biotech companies need to clean and preprocess the data to ensure its quality. This step involves identifying and correcting errors, imputing missing values, and standardizing formats. The time needed for data cleaning depends on the complexity of the data and the efficiency of the process.
Statistical Analysis: Biostatisticians analyze the data using statistical methods. They assess treatment efficacy, safety, and other relevant endpoints. The complexity of the statistical models, the volume of data, and the specific analyses required (e.g., survival analysis, regression, subgroup analyses) impact the time spent on this step.
Third-Party Involvement: When a third-party organization is responsible for data analysis, additional coordination is necessary. The biotech company and the third party must communicate, share data securely, and agree on analysis plans. The time taken depends on the efficiency of collaboration and the third party’s workload.
Quality Control and Validation: Rigorous quality control checks are essential to ensure accurate results. Biotech companies review the analysis outputs, validate statistical code, and verify findings. This process ensures data integrity but adds to the overall timeline.
Reporting and Interpretation: Once the analysis is complete, the results need to be summarized in reports or scientific publications. Interpretation, discussion, and drawing meaningful conclusions take time.
Regulatory Submissions: If the trial results are intended for regulatory submissions (e.g., to obtain drug approval), additional time is needed to prepare documentation and address any queries from regulatory agencies.
Summary:
Duration: The entire process can take several weeks to several months, depending on the trial’s complexity, data volume, and organizational efficiency.
Variability: Each trial is unique, so there is no fixed timeframe. Some trials may be expedited, while others require more time.
Collaboration: Effective communication and collaboration between the biotech company and the third party are crucial for timely analysis.
Remember thataccurate and thorough analysis is essential for making informed decisions indrug development. Rushing the process can compromise the quality of resultsand impact patient safety and scientific validity

Expand

Nice first post Jebby, I think the best part I took from that is this section I have in GREEN!

Lack of organisational skills and terrible at time lines!

After 20 plus years of being involved in bio-tech, why the hell would miller write "COMING WEEKS" surely she would know better than that!

So that Leeds to my conclusion that something else is going on in regards to maybe - peer review taking place, BP and the talked of privacy agreements, or they are just shite At completing their jobs and have absolutely zero regard for the share holders, THE ONES PAYING THEIR INFLATED WAGES!

No.	Vol.	Price($)
9	1639605	1.9¢

No.

Vol.

Price($)

1639605

1.9¢

Price($)	Vol.	No.
2.0¢	80000	1

Price($)

Vol.

No.

2.0¢

80000

No.	Vol.	Price($)
9	1639605	0.019
11	2301165	0.018
5	688000	0.017
11	1524225	0.016
4	660000	0.015

No.

Vol.

Price($)

1639605

0.019

2301165

0.018

688000

0.017

1524225

0.016

660000

0.015

Price($)	Vol.	No.
0.020	80000	1
0.021	188000	3
0.022	600000	2
0.023	307000	2
0.024	255035	3

Price($)

Vol.

No.

0.020

80000

0.021

188000

0.022

600000

0.023

307000

0.024

255035

(20min delay)
Last 1.9¢		Change 0.000(0.00%)		Mkt cap ! $17.14M

Open	High	Low	Value	Volume
1.9¢	1.9¢	1.9¢	$4.225K	222.3K

Nice first post Jebby, I think the best part I took from that is...

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

Trump is President Again: What Does This Mean for Crypto?

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Nice first post Jebby, I think the best part I took from that is...

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Burgeoning NZ insurance claims drive 1H25 operating loss for nib

Actinogen receives $9M R&D tax rebate to fund Alzheimer's trial

Trump is President Again: What Does This Mean for Crypto?

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News